51 Results

People

  1. Landgren
    Landgren
  2. Roshal
    Roshal
  3. Lesokhin
    Lesokhin
  4. Landau
    Landau
  5. Mailankody
    Mailankody
  6. Chung
    Chung
  7. Hassoun
    Hassoun
  8. Giralt
    Giralt
  9. Hultcrantz
    Hultcrantz
  10. Korde
    Korde

Groups

  1. Center for Hematologic Malignancies (51)
  2. Department of Medicine (51)
  3. Hematologic Malignancies Research (51)
  4. Hematologic Malignancies, Division of (51)
  5. Myeloma (42)
  6. Bone Marrow Transplant (29)
  7. Epidemiology and Biostatistics (29)
  8. Sloan Kettering Institute Postdocs (29)
  9. Survivorship Research (28)
  10. Biostatistics Service (20)
  1. "Hematologic Malignancies Research"
  2. "Mikhail Roshal"
Formats
  1. Meeting Abstract (26)
  2. Journal Article (21)
  3. Review (2)
  4. Correspondence (1)
  5. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (51)
  2. Department of Medicine (51)
  3. Hematologic Malignancies Research (51)
  4. Hematologic Malignancies, Division of (51)
  5. Myeloma (42)
  6. Bone Marrow Transplant (29)

More Groups

People
  1. Mikhail Roshal (51)
  2. Carl Landgren (31)
  3. Ahmet Dogan (29)
  4. Alexander Lesokhin (27)
  5. Heather Landau (23)
  6. Malin Hultcrantz (23)

More People

Years
  1. 2023 (3)
  2. 2022 (9)
  3. 2021 (8)
  4. 2020 (6)
  5. 2019 (7)
  6. 2018 (8)

More Years

Publications
  1. Blood (22)
  2. Blood Advances (3)
  3. Clinical Lymphoma, Myeloma and Leukemia (2)
  4. Journal of Molecular Diagnostics (2)
  5. Leukemia and Lymphoma (2)
  6. Modern Pathology (2)

More Publications

Publishers
  1. American Society of Hematology (25)
  2. Elsevier Inc. (3)
  3. Elsevier Science, Inc. (3)
  4. Nature Research (3)
  5. American Association for Cancer Research (2)
  6. Massachusetts Medical Society (2)

More Publishers

Results (51)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • GPRC5D-targeted CAR T cells for myeloma
    Journal Article

    Mailankody, S.; Devlin, S. M.; Landa, J.; Nath, K.; Diamonte, C.; Carstens, E. J.; Russo, D.; Auclair, R.; Fitzgerald, L.; Cadzin, B.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: A preclinical model and initial clinical experience
    Journal Article

    Palomba, M. L.; Qualls, D.; Monette, S.; Sethi, S.; Dogan, A.; Roshal, M.; Senechal, B.; Wang, X.; Rivière, I.; Sadelain, M.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy
    Journal Article

    Wudhikarn, K.; Flynn, J. R.; Rivière, I.; Gönen, M.; Wang, X.; Senechal, B.; Curran, K. J.; Roshal, M.; Maslak, P. G.; Geyer, M. B.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
    Research Letter

    Korde, N.; Mastey, D.; Tavitian, E.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Shah, U.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • Minimal residual disease in multiple myeloma: Defining the role of next generation sequencing and flow cytometry in routine diagnostic use
    Review

    Maclachlan, K. H.; Came, N.; Diamond, B.; Roshal, M.; Ho, C.; Thoren, K.; Mayerhoefer, M. E.; Landgren, O.; Harrison, S.
    Pathology (2021)

    Fulltext@MSK | Save
  • Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity
    Review

    Diamond, B. T.; Rustad, E.; Maclachlan, K.; Thoren, K.; Ho, C.; Roshal, M.; Ulaner, G. A.; Landgren, C. O.
    Blood Reviews (2021)

    Fulltext@MSK | Save
  • Routine evaluation of minimal residual disease in myeloma using next-generation sequencing clonality testing: Feasibility, challenges, and direct comparison with high-sensitivity flow cytometry
    Journal Article

    Ho, C.; Syed, M.; Roshal, M.; Petrova-Drus, K.; Moung, C.; Yao, J.; Quesada, A. E.; Benhamida, J.; Vanderbilt, C.; Liu, Y.; more...
    Journal of Molecular Diagnostics (2021)

    Fulltext@MSK | Save